Navigation Links
Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis' New Headquarters

Regenerative Medicine leader to expand space and employees in

Massachusetts, encompassing over 250,000 square feet for new global


CANTON, Mass., April 3, 2008 /PRNewswire/ -- Joined by local officials and Organogenesis, Inc.'s CEO Geoff MacKay, Governor Deval Patrick announced today that the Massachusetts-based company, which was once planning to move its operations outside of the state, is initiating an expansion of its global headquarters, R&D and manufacturing facilities in Canton.

The Governor's $1 billion Life Sciences Initiative was credited by Organogenesis, the world's leading regenerative medicine company, as a deciding factor in the company's decision to remain and expand in Massachusetts and thereby add hundreds of highly skilled jobs.

"I am pleased that Organogenesis will continue to build its future here in Massachusetts," said Governor Patrick, "This announcement speaks to our commitment to the long-term growth of this industry."

The Massachusetts Office of Business Development worked closely with Organogenesis to create a $12.9 million incentive package. In addition, the state has facilitated $5 million in low-interest loans for growth initiatives. The Life Sciences Initiative bill also addresses tax inequalities when compared with competing states.

"When we first began speaking to the office of Economic Development early last year, Organogenesis had 200 employees, and today, we have 325 with open positions for an additional 50 jobs in 2008 -- all of these being high-skilled positions," said Organogenesis CEO Geoff MacKay. "Driven by both existing high revenue growth and major regulatory approvals, we are well on target for doubling our workforce."

"Governor Patrick, Secretary O'Connell as well as House and Senate leadership, have made a significant commitment to the life sciences sector and we are pleased to see their efforts coming to fruition," continued MacKay. "The Life Sciences Initiative bill solidifies the state of Massachusetts as the best place in the world to translate potentially life saving research into viable, successful businesses."

Currently located at 150 Dan Road, Canton, the new Organogenesis headquarters campus comprises three large buildings encompassing more than 250,000 square feet and within 100 yards of each other:

85 Dan Road

-- Corporate offices will occupy this facility

-- 78,000+ square feet, including 40,000 square feet of currently

built-out office space (the remaining space is empty open bay for


-- Upgrades may add up to 10,500 square feet to the building footprint

150 Dan Road

-- To become main research and development labs and pilot manufacturing

site for smaller product lines

-- 79,000+ square feet

275 Dan Road

-- To become main manufacturing facility, including 60,000 square feet of

manufacturing and quality labs, as well as shipping/receiving and

other support systems

-- 95,000+ square feet

Founded in 1985 to commercialize technologies initially discovered at the Massachusetts Institute of Technology (MIT), Canton-based Organogenesis delivers living cell therapy "on demand" to medical clinics. Organogenesis' signature product, Apligraf(R), is the first bio-engineered living cell therapy to have received FDA approvals to close diabetic foot ulcers and venous leg ulcers.

Unveiled last spring, Governor Patrick's life sciences plan includes a 10-year, $1 billion investment package that will both enhance the Commonwealth's already nationally recognized assets in the fields of medicine and science, and fill gaps in federal funding to ensure the state's ability to support life science progress from the idea stage through the production and commercialization stages. Key to the Governor's Life Science Initiative is new legislation that will strengthen the Massachusetts Life Science Center and charge it with the execution of a life science mission focused on science and economic development, strategic investments at critical stages of the development cycle, and collaboration with the private sector to create innovation infrastructure critical to both researchers and companies.

About Regenerative Medicine

A new frontier in healthcare, regenerative medicine utilizes living human cells, including stem cells, to repair or replace body tissue damaged by injury, disease or even the natural aging process.

Regenerative medicine is a multidisciplinary field which brings together biology, medicine, and engineering to empower scientists to grow living cells, tissues and organs in the laboratory, and to safely implant them into the human body for the purposes of healing.

About Organogenesis, Inc.

Massachusetts based Organogenesis, Inc. is the world's most successful regenerative medicine company and is focused in areas of bio-active wound healing, bio-surgery and bio-aesthetics. Organogenesis delivers living tissue "on demand," and its mission is to bring the medical marvel of regenerative medicine products to patients and to standardize their use in everyday medical care.

Organogenesis is in the midst of a large expansion, both in the U.S., as well as overseas. As the world's leading Regenerative Medicine company, Organogenesis has broadened its international scope and ties over the past few years. The company has recently established European headquarters located in Switzerland. In addition, last December the company announced an agreement with China's National Tissue Engineering Center (NTEC), a leading stem cell and regenerative medicine consortium, headquartered in Shanghai, for the commercialization of Organogenesis, Inc. technology within the Chinese market, and potentially throughout Asia. For more information, visit

SOURCE Organogenesis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MichBio Responds to Governors Plan to Repeal Tort Reform Laws
2. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
3. MUSCs Kilpatrick to Address Congress Regarding PTSD Care
4. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
5. Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Dendreon Announces $47 Million Registered Direct Offering
8. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
9. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
10. MiMedx Group Announces Post-split Name Change
11. Millennium Announces $200,000 Purchase Order From Greek Distributor
Post Your Comments:
(Date:6/27/2016)... /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... shareholders, Clean Technology Fund I, LP and Clean Technology ... based venture capital funds which together hold approximately 59% ... diluted, as converted basis), that they have entered into ... holdings in Biorem to TUS Holdings Co. Ltd. ("TUS") ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... have just published their findings on what they believe could be a new ... summary of the new research. Click here to read it now. ...
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... ) The integration ... security to access and transact across channels. Using ...
Breaking Biology News(10 mins):